Original ArticlesOctreotide negates the benefit of galantide when used in the treatment of caerulein-induced acute pancreatitis in mice-Science-Chemical Encyclopedia-lookchem

Original ArticlesOctreotide negates the benefit of GALANTIDE (cas 138579-66-5) when used in the treatment of caerulein-induced acute pancreatitis in mice
Add time:09/03/2019 Source:sciencedirect.com

BackgroundWe have previously shown that GALANTIDE (cas 138579-66-5), a non-specific galanin receptor antagonist, ameliorates acute pancreatitis (AP) induced in mice. Octreotide, a somatostatin analogue, has been used in the treatment of AP with inconsistent outcomes. This study set out to compare the efficacy of a combined treatment of galantide and octreotide with the efficacy of each agent individually in experimental AP.

We also recommend Trading Suppliers and Manufacturers of GALANTIDE (cas 138579-66-5). Pls Click Website Link as below: cas 138579-66-5 suppliers

Prev:Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles
Next: The efficacy of combining feG and GALANTIDE (cas 138579-66-5) in mild caerulein-induced acute pancreatitis in mice)

Click to view details

Encyclopedia